Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical’s subsidiary, Ningbo Fuying, has entered into agreements to acquire substantial equity interests in Nanjing Fund, Dalian Xingweilai Fund, and Suzhou Angel Fund from Fosun High Tech. This acquisition will significantly boost the Group’s equity stakes in these funds, enhancing its control and influence. These transactions are classified as connected transactions under Hong Kong listing rules but are exempt from requiring independent shareholder approval.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.